ArticleClinical rheumatology2026
Association between colonoscopic findings and fecal calprotectin levels in familial Mediterranean fever patients with gastrointestinal symptoms: a retrospective cohort study.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionFamilial Mediterranean fever (FMF) is an autoinflammatory disease characterized by recurrent fever and serositis. Gastrointestinal involvement and subclinical intestinal inflammation have been reported in FMF, with elevated fecal calprotectin (FC) levels even during attack-free periods. This study aimed to investigate the relationship between colonoscopic findings and FC levels in pediatric FMF patients presenting with gastrointestinal symptoms.
methodsThis retrospective cohort study included children under 18 years of age with FMF who underwent colonoscopy for gastrointestinal symptoms between 2018 and 2024. Patients were categorized into three groups based on colonoscopic findings: normal colonoscopy, nonspecific findings, and inflammatory bowel disease (IBD). Demographic data, laboratory results, and FC levels were analyzed. ROC analysis was performed to identify the FC cutoff value predictive of colitis.
resultsA total of 81 patients (median age 12 years; 51.9% male) were included. FC levels were significantly higher in the IBD group compared to other groups (p < 0.001). Albumin levels were lower in IBD patients (p = 0.013). ROC analysis revealed that an FC level below 123 µg/g predicted normal colonoscopic findings with 89.8% sensitivity and 84.4% specificity (AUC 0.902).
conclusionFC may serve as a useful non-invasive biomarker for predicting colonoscopic abnormalities in pediatric FMF patients. An FC level below 123 µg/g appears to reliably predict normal colonoscopic findings, suggesting that unnecessary invasive procedures may be avoided in this subgroup. Key Points • Fecal calprotectin levels correlated with the severity of colonoscopic abnormalities in FMF patients with gastrointestinal symptoms. • A fecal calprotectin level below 123 µg/g feces strongly predicted normal colonoscopic findings. • Fecal calprotectin may serve as a useful non-invasive tool to reduce unnecessary colonoscopic procedures in pediatric FMF patients.
Indexed as
Identifiers
42313236What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.